IP AUSTRALIA
AUSTRALIAN PATENT OFFICE
Southern Cross Pharma Ltd v Euro-Celtique S.A. [2016] APO 61
Patents:2002300863 & 2009243527
Title:Controlled Release Formulation
Patentee: Euro-Celtique S.A.
Opponent: Southern Cross Pharma Pty Ltd
Delegate: Dr B. Akhurst
Decision Date: 21 September 2016
Hearing Date: Written submissions filed on 23 August and 6 September 2016
Catchwords: PATENTS – Final determination of oppositions to extensions of the term of two pharmaceutical patents – whether additional information provided by the patentee overcomes the deficiencies in the extension requests identified in the earlier decision – extensions granted.
Representation: Counsel for the patentee: Philip Kerr.
Patent attorney for the applicant: Allens Patent and Trade Mark Attorneys.
Patent attorney for the opponent: Duncan Bucknell Company.
IP AUSTRALIA
AUSTRALIAN PATENT OFFICE
Patent Application: 2002300863 & 2009243527
Title:Controlled Release Formulation
Patentee: Euro-Celtique S.A.
Date of Decision: 21 September 2016
DECISION
The further information provided by Euro-Celtique S.A overcomes the deficiencies identified in the earlier decision published as Southern Cross Pharma Ltd v Euro-Celtique S.A. [2016] APO 1.
Subject to an appeal of this decision, I grant the extensions to the term of patents 2002300863 and 2009243527.
REASONS FOR DECISION
This matter concerns the final determination of applications by Euro-Celtique S.A. to extend the term of patents 2002300863 and 2009243527 and the oppositions by Southern Cross Pharma Pty Ltd. The date of these patents is 9 May 1994 and their maximum 20-year term expired on 9 May 2014. If extensions are granted the term of each patent would be extended until 21 September 2015.
Background
On 7 May 2014, Euro-Celtique S.A. (the patentee) applied to extend the term of three patents including 2002300863 (‘863) and 2009243527 (‘527). On 10 September 2014, Southern Cross Pharma Pty Ltd (the opponent) opposed grant of the extensions. The matters were heard and in Southern Cross Pharma Ltd v Euro-Celtique S.A. [2016] APO 1 (the earlier decision), I found the oppositions to extend the term of patents ‘863 and ‘527 were successful due to deficiencies in the extension requests. However, I allowed the patentee a period of time to provide further information in order to overcome the deficiencies.
As the basis for its extension request, the patentee relied on the product Tramal® SR 100, which was developed by Grunenthal GmbH and is manufactured by them under licence from the patentee. Thus, on 15 February 2016 the patentee advised that the further information it sought to file was proprietary and confidential and as a consequence it requested a confidentiality order. The opponent requested a hearing and in Southern Cross Pharma Ltd v Euro-Celtique S.A. [2016] APO 44, the Deputy Commissioner directed under reg 4.3(2)(b) that the patentee’s evidence containing the further information, when filed, should not be open to inspection, but it would be available for inspection by the opponent subject to specified conditions. The patentee subsequently filed the further information on 17 August 2016. Note that the information in this decision which is subject to…
Keep reading for free
Create a free CaseChat account to read Southern Cross Pharma Ltd v Euro-Celtique S.A and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [2016] APO 61
- Decision Date
CaseChat Overview and Summary
The court considered the specific requirements for patent term extensions under sections 70 and 71 of the relevant Act, as well as Regulation 6.8 and Regulation 6.11. Section 70 sets out the conditions for the extension of a patent term, while section 71 prescribes the form and timing of an application. Regulation 6.8 mandates the information required to accompany an application for extension of the term of a standard patent, and Regulation 6.11 allows for the Commissioner to request further information if the application is deficient.
The court noted that in the earlier decision, it had found the oppositions to the extensions of patents 2002300863 and 2009243527 to be successful due to deficiencies in the extension requests. Specifically, the patentee had not provided the weight-for-weight proportions of certain ingredients in the pharmaceutical product TRAMAL® SR 100. The patentee was then given an opportunity to provide further information to overcome these deficiencies. The further information included detailed weight-for-weight percentages of the polymers and other ingredients in TRAMAL® SR 100, demonstrating that the product met the requirements set forth in the patent claims.
After reviewing the additional information, the court concluded that the further information provided by Euro-Celtique S.A. adequately addressed the deficiencies identified in the earlier decision. The court found that the TRAMAL® SR 100 product contained the necessary ingredients in the required proportions, thereby satisfying the conditions for the patent term extensions. As a result, the court granted the applications to extend the term of patents 2002300863 and 2009243527, subject to any potential appeal of this decision.
Orders
Orders of the court
Full text does not contain this section.
Background
Background to the litigation
Full text does not contain this section.
Evidence
Evidence Before The Court
Full text does not contain this section.
Decision
Reasons for decision
Full text does not contain this section.
Ratio Decidendi
Legal Principle Established
Full text does not contain this section.